HollyLynnPacentaMD

PubMed

• Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-...
  Valentin Barsan, Yimei Li, Snehit Prabhu, Christina Baggott, Khanh Nguyen, Holly Pacenta, Christine L Phillips, Jenna Rossoff, Heather Stefanski, Julie-An Talano, Amy ...> ;Eclinicalmedicine. 2023 Nov 1
• 1 citations
  HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.
  Kevin O McNerney, Stephanie J Si Lim, Kyle Ishikawa, Alexandra Dreyzin, Anant Vatsayan, John J Chen, Christina Baggott, Snehit Prabhu, Holly L Pacenta, Christine Phili...> ;Blood Advances. 2023 Jun 27
• 21 citations
  Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.
  Heather E Stefanski, Anne Eaton, Christina Baggott, Jenna Rossoff, Michael R Verneris, Snehit Prabhu, Holly L Pacenta, Christine L Phillips, Julie-An Talano, Amy Mosko...> ;Blood Advances. 2023 Feb 28
• 22 citations
  Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.
  Liora M Schultz, Anne Eaton, Christina Baggott, Jenna Rossoff, Snehit Prabhu, Amy K Keating, Christa Krupski, Holly Pacenta, Christine L Philips, Julie-An Talano, Amy ...> ;Journal of Clinical Oncology. 2023 Jan 10
• Mediport use as an acceptable standard for CAR T cell infusion.
  Toner, K. N., De Oliveira, S. N., Maya Eylon, Snehit Prabhu, Samuel John, Maxwell J M King, Dhruv Bhatt, Kevin J Curran, Courtney Erickson, Nicole A Karras, Christine ...> ;Frontiers in Immunology. 2023 Jan 1
• 21 citations
  Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
  Amy Moskop, Lauren Pommert, Christina Baggott, Snehit Prabhu, Holly L Pacenta, Christine L Phillips, Jenna Rossoff, Heather E Stefanski, Julie-An Talano, Steve P Margo...> ;Blood Advances. 2022 Jul 26
• 68 citations
  Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen R...
  Liora M Schultz, Christina Baggott, Snehit Prabhu, Holly L Pacenta, Christine L Phillips, Jenna Rossoff, Heather E Stefanski, Julie-An Talano, Amy Moskop, Steven P Mar...> ;Journal of Clinical Oncology. 2022 Mar 20
• 4 citations
  Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia.
  Jenna Rossoff, Christina Baggott, Snehit Prabhu, Holly L Pacenta, Christine L Phillips, Heather E. Stefanski, Julie-An Talano, Amy Moskop, Steven P. Margossian, Michae...> ;Blood. 2021 Nov 25
• 30 citations
  Tisagenlecleucel Outcomes in Relapsed/Refractory Extramedullary ALL: A Pediatric Real World CAR Consortium Report.
  Vanessa A Fabrizio, Christine L Phillips, Adam Lane, Christina Baggott, Snehit Prabhu, Emily Egeler, Sharon Mavroukakis, Holly L Pacenta, Jenna Rossoff, Heather E. Ste...> ;Blood Advances. 2021 Nov 18
• 38 citations
  Optimal fludarabine lymphodepletion is associated with improved outcomes following CAR T-cell Therapy.
  Vanessa A Fabrizio, Jaap Jan Boelens, Audrey Mauguen, Christina Baggott, Snehit Prabhu, Emily Egeler, Sharon Mavroukakis, Holly L Pacenta, Christine L Phillips, Jenna ...> ;Blood Advances. 2021 Nov 17
• 9 citations
  Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force
  Holly L Pacenta, Wendy Allen-Rhoades, David M. Langenau, Peter J. Houghton, Charles Keller, Christine M. Heske, Michael D. Deel, Corinne M. Linardic, Jack F. Shern, El...> ;Journal of Clinical Medicine. 2021 Apr 1
• 40 citations
  Recent progress in the treatment of cancer in children
  Erin Butler, Kathleen Ludwig, Holly L Pacenta, Laura J. Klesse, Tanya C. Watt, Theodore W. Laetsch> ;CA. 2021 Apr 1
• 9 citations
  CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia
  Holly L Pacenta, Theodore W. Laetsch, Samuel John> ;Paediatric Drugs. 2020 Feb 1
• 31 citations
  Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
  Holly L Pacenta, Margaret E. Macy> ;Drug Design, Development and Therapy. 2018 Oct 23
• 37 citations
  Chemokine receptor CXCR4 signaling modulates the growth factor-induced cell cycle of self-renewing and multipotent neural progenitor cells.
  Meizhang Li, Cathleen Chang, Justin D. Lathia, Li Wang, Holly L. Pacenta, Anne C. Cotleur, Richard M. Ransohoff> ;Glia. 2011 Jan 1
• Join now to see all

Journal Articles

• Chemokine receptor CXCR4 signaling modulates the growth factor-induced cell cycle of self- renewing and multipotent neural progenitor cells.  
  Li M, Chang CJ, Lathia JD, Wang L, Pacenta HL, Cotleur A, Ransohoff RM., Glia, 1/2011
• Continuous tunneled femoral nerve block for palliative care of a patient with metastatic osteosarcoma  
  Pacenta HL, Kaddoum RN, Pereiras LA, Chidiac EJ, Burgoyne LL., Anaesthesia Intensive Care., 5/2010